论文部分内容阅读
目的:观察候选新中药天升元口服液对免疫介导的再生障碍性贫血(immune-mediated aplastic anemia,IAA)模型小鼠的效应。方法:建立IAA小鼠模型,给予天升元口服液14 d后,检测外周血白细胞(WBC)、红细胞(RBC)、血红蛋白(HGB)、红细胞比积(HCT)、血小板(PLT)、网织红细胞(RET)、股骨骨髓有核细胞(BMNC)和脾脏指数,并进行股骨和脾脏病理形态学观察。结果:模型对照组WBC,RBC,HGB,HCT,PLT,RET,BMNC和脾脏指数均较正常对照组显著下降(P<0.001);而天升元口服液(12.4,24.8 g.kg-1.d-1)能显著升高模型小鼠WBC(升幅分别达150%和133.3%),RBC(9.5%和37.1%),HGB(12.9%和44.5%),HCT(11.6%和28.4%),PLT(94.8%和252.3%),RET(115.4%和123.1%),BMNC(71.1%和95.6%)和脾脏指数(18.7%和33.7%),与模型组比较差异显著(P<0.05～0.001)。病理学检查显示天升元口服液明显增加骨髓造血细胞,降低脂肪细胞产生,减轻脾小体萎缩状态,促进脾小体髓外造血灶产生。结论:天升元口服液通过促进骨髓内外造血细胞增殖,改善造血功能,产生对IAA模型小鼠的治疗效应。
Objective: To observe the effect of candidate new Chinese medicine Tianshengyuan oral liquid on immune-mediated aplastic anemia (IAA) model mice. Methods: IAA mouse model was established. Tianshengyuan oral solution was administered for 14 days to detect the expression of WBC, RBC, HGB, HCT, PLT, (RET), femur bone marrow nucleated cells (BMNC) and spleen index, and pathomorphological observation of the femur and spleen. Results: Compared with the normal control group, WBC, RBC, HGB, HCT, PLT, RET, BMNC and spleen index decreased significantly in the model control group (P <0.001) (-1.5% and 37.1%), HGB (12.9% and 44.5%), HCT (11.6% and 28.4%), (94.8% vs 252.3%), RET (115.4% and 123.1%), BMNC (71.1% and 95.6%) and spleen index (18.7% and 33.7%, respectively) . Pathological examination showed that Tianshengyuan oral liquid obviously increased bone marrow hematopoietic cells, reduced the production of adipocytes, reduced the atrophy state of spleen, and promoted the extramedullary hematopoietic foci. Conclusion: Tianshengyuan oral liquid can improve the hematopoietic function by promoting the proliferation of hematopoietic cells both in vitro and in vivo, and produce therapeutic effects on IAA model mice.